<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348150</url>
  </required_header>
  <id_info>
    <org_study_id>M15PEC</org_study_id>
    <secondary_id>2015-005695-15</secondary_id>
    <secondary_id>NL56123.031.15</secondary_id>
    <nct_id>NCT03348150</nct_id>
  </id_info>
  <brief_title>Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.</brief_title>
  <acronym>PERISCOPE II</acronym>
  <official_title>Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled two-armed phase III trial for gastric cancer patients with peritoneal&#xD;
      dissemination. Randomization between gastrectomy + cytoreductive surgery + HIPEC&#xD;
      (experimental arm) and palliative systemic chemotherapy (standard arm).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: For gastric cancer patients with peritoneal carcinomatosis palliative systemic&#xD;
      chemotherapy is the standard treatment in the Netherlands. There are no potentially curative&#xD;
      treatment options. Peritoneal carcinomatosis, in contrast to lymphatic and haematogenous&#xD;
      dissemination, should be regarded as locoregional extension of disease. Administering&#xD;
      chemotherapeutic drugs directly into the peritoneal cavity has an advantage over systemic&#xD;
      chemotherapy since high concentrations of cytotoxic drugs can be delivered directly into the&#xD;
      peritoneal cavity with little systemic toxicity. The combination of intraperitoneally&#xD;
      administered chemotherapy with cytoreductive surgery and a radical gastrectomy has shown&#xD;
      promising results in gastric cancer patients in Asia. As with other gastric cancer issues,&#xD;
      the results obtained in Asian patients cannot be extrapolated directly to Western patients.&#xD;
&#xD;
      Objective: The primary aim of this study is to compare the overall survival between gastric&#xD;
      cancer patients with limited peritoneal carcinomatosis and/ or tumour positive peritoneal&#xD;
      cytology treated with gastrectomy, cytoreductive surgery and HIPEC and those treated with the&#xD;
      current standard treatment, i.e. palliative systemic chemotherapy.&#xD;
&#xD;
      Study design : This is a multicentre randomised controlled two-armed phase III trial.&#xD;
      Patients will be randomised (1:1) between palliative systemic chemotherapy only (standard&#xD;
      treatment) and gastrectomy combined with cytoreductive surgery and HIPEC (experimental&#xD;
      treatment).&#xD;
&#xD;
      Study population: Gastric cancer patients are eligible for inclusion if (1) the primary&#xD;
      cT3-cT4 gastric tumour including regional lymph nodes is considered to be resectable, (2)&#xD;
      limited peritoneal carcinomatosis (&lt;7) and/ or tumour positive cytology is confirmed by&#xD;
      laparoscopy or laparotomy, and (3) systemic chemotherapy (prior to inclusion) was without&#xD;
      disease progression.&#xD;
&#xD;
      Main study parameters/endpoints: The study sample size (182 patients) is calculated from the&#xD;
      hypothesis that the median overall survival of the patients treated according to protocol in&#xD;
      the experimental arm is 18 months, as compared to a median overall survival of 10 months in&#xD;
      the standard arm. Statistical analysis will be done according to the intention-to-treat&#xD;
      principle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>To compare the overall survival between gastric cancer patients with limited peritoneal carcinomatosis and/ or tumour positive peritoneal cytology treated with gastrectomy, cytoreductive surgery and HIPEC and those treated with the current standard treatment, i.e. palliative systemic chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>To compare the progression free survival between gastric cancer patients with limited peritoneal carcinomatosis and/ or tumour positive peritoneal cytology treated with gastrectomy, cytoreductive surgery and HIPEC and those treated with the current standard treatment, i.e. palliative systemic chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>To study treatment-related toxicity in gastric cancer patients with limited peritoneal carcinomatosis and/ or tumour positive peritoneal cytology treated with gastrectomy, cytoreductive surgery and HIPEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs and health benefits</measure>
    <time_frame>5 years</time_frame>
    <description>To compare the costs and health benefits of a gastrectomy in combination with cytoreductive surgery and HIPEC, to the costs and health benefits of standard palliative systemic chemotherapy in patients with limited peritoneal carcinomatosis and/ or tumour positive peritoneal cytology.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Stomach Neoplasm</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Gastrecomy + Cytoreductive surgery + HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>palliative systemic chemotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive surgery + Gastrecomy</intervention_name>
    <description>Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.</description>
    <arm_group_label>Gastrecomy + Cytoreductive surgery + HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</intervention_name>
    <description>HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)</description>
    <arm_group_label>Gastrecomy + Cytoreductive surgery + HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Biopsy proven primary adenocarcinoma (or undifferentiated carcinoma) of the stomach.&#xD;
             Including tumours at the oesophagogastric junction provided that the bulk of the&#xD;
             tumour is located in the stomach, and, the intended surgical treatment is a gastric&#xD;
             resection and not an oesophagectomy. A high intra-thoracic anastomosis is allowed, but&#xD;
             not if a thoracotomy is necessary.&#xD;
&#xD;
          -  cT3-cT4 tumour (TNM classification, 7th edition), considered to be resectable&#xD;
             (including lymph nodes)&#xD;
&#xD;
          -  Limited peritoneal carcinomatosis (PCI &lt;7) and/ or tumour positive peritoneal cytology&#xD;
             confirmed by laparoscopy or laparotomy and proven by pathological examination&#xD;
&#xD;
          -  Treatment with systemic chemotherapy, with the latest course ending within 8 weeks&#xD;
             prior to inclusion. All currently standard chemotherapy regimens are acceptable&#xD;
&#xD;
          -  Absence of disease progression during systemic chemotherapy (prior to inclusion)&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function. Minimally acceptable laboratory&#xD;
             values at start of the study inclusion:&#xD;
&#xD;
               -  ANC ≥ 1.5 x 109 /L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109 /L&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x ULN, and ALAT and ASAT ≤ 2.5 x ULN&#xD;
&#xD;
               -  Creatinine clearance ≥ 50 ml/min (measured or calculated by Cockcroft-Gault&#xD;
                  formula)&#xD;
&#xD;
          -  For female patients who are not sterilised or in menopause (i.e., amenorrhea ≥1 year&#xD;
             if age ≥60 years, or ≥2 years if age &lt;60 years):&#xD;
&#xD;
               -  negative pregnancy test (urine/serum)&#xD;
&#xD;
               -  no breast feeding or active pregnancy ambition&#xD;
&#xD;
               -  reliable contraceptive methods&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastases (e.g., liver, lung, para-aortic lymph nodes; i.e., stations 14 and&#xD;
             16) or small bowel dissemination&#xD;
&#xD;
          -  Recurrent gastric cancer&#xD;
&#xD;
          -  Prior resection of the primary gastric tumour&#xD;
&#xD;
          -  Non-synchronous peritoneal carcinomatosis&#xD;
&#xD;
          -  Current other malignancy (other than cervix carcinoma and basalioma)&#xD;
&#xD;
          -  Uncontrolled infectious disease or known infection with Human Immunodeficiency Virus&#xD;
             type -1 or -2&#xD;
&#xD;
          -  A known history of hepatitis B or C with active viral replication&#xD;
&#xD;
          -  Recent myocardial infarction (&lt; 6 months) or unstable angina&#xD;
&#xD;
          -  Any medical condition not yet specified above that is considered to interfere with&#xD;
             study procedures, including adequate follow-up and compliance and/or would jeopardise&#xD;
             safe treatment&#xD;
&#xD;
          -  Known hypersensitivity for any of the applied chemotherapeutic agents and/or their&#xD;
             solvents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna van Sandick, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surgeon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen van der Sluis, MSc</last_name>
    <phone>+31 20 512 2954</phone>
    <email>k.vd.sluis@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek/ Netherlands Cancer institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen van der Sluis, MSc</last_name>
      <phone>+31 20 512 2954</phone>
      <email>k.vd.sluis@nki.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, Schellens JH, Aalbers AG, Huitema AD, Knibbe CA, Boerma D, Wiezer MJ, van Ramshorst B, van Sandick JW. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. JMIR Res Protoc. 2017 Jul 13;6(7):e136. doi: 10.2196/resprot.7790.</citation>
    <PMID>28705789</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIPEC</keyword>
  <keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
  <keyword>gastrectomy</keyword>
  <keyword>cytoreductive surgery</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

